To evaluate 68Ga-DOTATATE PET/CT for staging of patients with carcinoid, neuroendocrine tumors, medullary thyroid cancer and other cancers expressing somatostatin receptors.
This is an expanded access study with a total of 300 participants with NET and suspected SSTR positive tumors. Eligible participants will undergo baseline assessments at enrollment. Study participants will receive 68Ga-DOTATATE and will undergo a PET/CT imaging study. All patients referred by Oncologists will be screened by a UCLA Nuclear Medicine physician and then accepted for scanning if clinically appropriate.
Study Type
EXPANDED_ACCESS
Patients with somatostatin receptor positive tumors will be evaluated with 68Ga-DOTATATE PET/CT.
UCLA Hospital
Los Angeles, California, United States
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.